The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures. 

Witness Ge Bai, an associate professor at Johns Hopkins University’s Carey Business School and Bloomberg School of Public Health, said Congress should require drug makers to disclose their financial relationships with independent patient assistance programs and patient advocacy organizations and their free drug samples to clinicians. She said these transactions “can undermine the best interests of patients and their insurance plans while benefiting drug manufacturers financially.”   

Juliana Keeping, communications director for Patients for Affordable Drugs and the mother of a child with cystic fibrosis, also urged Congress to “eliminate the need for patient assistance programs by making drug costs affordable and cost-sharing manageable.” 

Tara O’Neill Hayes, director of human welfare policy for the American Action Forum, called for changes to the Part D benefit to remove “perverse incentives for insurers and drug manufacturers to benefit from high-cost drugs.” 

Steven Tananbaum, a senior fellow for the Council on Foreign Relations, recommended Congress remove incentives for drug makers to move profits and production offshore.

In December, the House of Representatives passed H.R. 3, legislation that would make changes to the Medicare program in an effort to lower prescription drug prices. 

Subcommittee Ranking Member Devin Nunes, R-Calif., said both parties “can work together to lower drug prices for families without reducing cures, but H.R. 3 is not the answer.” Instead, he voiced support for H.R. 19

Related News Articles

The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…
Another day, another misleading PhRMA-funded study that attempts to deflect blame for a growing crisis of their own making – the skyrocketing cost of…
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2018 data. The dashboards show…
The pharmaceutical industry’s latest “report” is an obvious attempt to divert attention away from a problem of their own making: skyrocketing drug prices. The…
Senate Finance Committee leaders Friday released changes to the Prescription Drug Pricing Reduction Act that would eliminate impending Medicaid cuts to…
The latest report from AIR340B, a group financed and backed by the pharmaceutical industry, continues to misrepresent a program with a more than 25-year…